Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 1

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Endocrine 6

Conditions

Carcinoma, Non-Small-Cell Lung 129Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 64Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

pembrolizumab 6Mitotane 5Cisplatin 5cabozantinib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Doxorubicin 3sodium thiosulfate 2relacorilant 2cixutumumab 2cemiplimab 2camrelizumab 2apatinib 2Radiotherapy 2Nivolumab 2Ipilimumab 2Etoposide 2Cytoreduction Surgical Procedures 2milademetan 1lenvatinib 1gossypol acetic acid 1dostarlimab 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Tamoxifen 1Suramin 1Sunitinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Adrenocortical Carcinoma × pembrolizumab × Clear all
NCT06066333 2026-04-15

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
12 enrolled
Endocrine

Adrenocortical Carcinoma

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

NCT05036434 2026-01-23

ACCOMPLISH

National Cancer Center, Korea

Phase 2 Active not recruiting
30 enrolled
Endocrine

Adrenocortical Carcinoma

NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT05563467 2025-04-02

PEMBR-01

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Recruiting
24 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡